ÂÜÀòÂÒÂ×

Mark W. Womack is an experienced executive in the biopharmaceutical and management consulting sectors, currently serving as Chief Executive Officer at BioCina and a board member for LumaCina and NovaCina. Womack has held prominent leadership roles, including CEO of KBI Biopharma and Stelis Biopharma, achieving significant revenue growth and operational advancements in global biologics CDMO organizations. As Chief Business Officer at AGC Biologics, Womack drove substantial increases in business sales and led strategic initiatives following major acquisitions. Womack's earlier career includes executive positions in management consulting, notably at Brooks International and Celerant Consulting, where transformational achievements in revenue and client engagement were realized. Academic credentials include an Executive Education Program from Harvard Business School, a Master of Science in Organization Development from Chapman University, and a Bachelor of Science in Education from Southern Illinois University, Carbondale.